Meeting: NextGen VP

Date: 2026-02-05 Attendees: Thomas Startz, Michael Yuan, Deborah Chu (NextGen VP) Type: Cold outreach / Intro + market color Duration: ~31 min Note: Transcript labels her "Deborah Chu" but meeting invite says "Deborah Chu" — may be a transcript error.

Context from Michael: "The texture of the call was quite awkward. Don't overindex on this one, but it is relevant as they are a VC."

Summary

Informational call initiated by Thomas's cold outreach. Deborah invests in digital health at pre-seed/seed. She was analytical and somewhat skeptical throughout — pushed hard on differentiation, defensibility, vision clarity, and whether this is a tech company or consulting firm. Her main feedback: the pitch needs a clearer end-state vision and the deep-vs-broad strategy needs to be resolved. She shared useful market intel (Fourier Health in portfolio, Lumara Health and Logical Health as comps). Ended with standard "keep me posted, potentially a fit" — lukewarm. More valuable as market intelligence and pitch feedback than as an active investor lead.

Questions Asked

#	Question (verbatim/near-verbatim)	Topic	Answer Quality	Notes
1	[Opening market color] "It's been hard to differentiate... underlying models are the same... hard to find things that are super differentiated and long term defensible"	Competition / Moat	N/A	Not a question — she was framing her skepticism. Important context for everything that followed.
2	"Are you positioning this more as a Palantir type model? Do you envision selling it to other payers with a forward deploy model, or embedding more deeply with the first two customers?"	Business Model / Strategy	decent	Thomas said both — deploy core product broadly + go deeper with existing. But she was probing for a choice and didn't get one.
3	"Why and how did you decide to do [UM] first?"	Market / Strategy	strong	Research, conferences, talked to nurses, repeatable text analysis, financial swing ($2-5K/case), complex space no one's in. Good answer.
4	"What has been or what do you expect to be your go-to-market approach?"	GTM	decent	Founder-led, Wharton relationships, conferences, top-down C-suite + bottom-up nurse hire. Honest but standard.
5	"So you guys are looking to raise a seed?"	Fundraise	decent	Confirmed. Mentioned capacity constraint with more clients.
6	"What's the long term vision? What do you ultimately want to get to?"	Vision	decent	Real-time payer-provider integration, eliminate payment delays, every payer with visibility into every patient. Ambitious but she pushed for more specificity.
7	"Does the product and contract values justify the initial [deployment] investment? Is there a roadmap to decreasing services upfront or enabling the customer to do more themselves? Or are we investing in a tech-enabled consulting firm long term?"	Scalability / Business Model	weak	Thomas: "We're still figuring this out too. The clients are figuring out how to pay for these things as well." Honest but this is the answer that most undermines confidence.
8	"What are the hypotheses that you are hoping to test?"	Vision / Strategy	decent	This was coaching, not a question. Thomas pivoted to: payer pressure hypothesis, United's cost cuts, utilization going up. Landed OK but felt improvised.

Concerns Raised

Differentiation is hard — She opened with this. "Underlying models are the same... people try to make arguments around being embedded in workflows... hard to find things that are super differentiated." This framed her entire evaluation.
Vision clarity — "If you're going to raise venture dollars, you need a pretty clear vision of the end state and a strong opinion on the direction the market is headed." She explicitly said the pitch needs more clarity on deep vs. broad.
Consulting firm risk — "Are we just investing in a tech-enabled consulting firm long term?" Same scalability concern as Refract, but stated more bluntly.
"Still figuring it out" — Thomas said this about pricing/business model. She was polite about it but it's clearly a yellow flag.
Moat question echoed back — Thomas himself raised the moat issue ("what's the defensibility if these products are so cross-applicable?"). This was honest but may have planted more doubt than confidence.

What Resonated

FDE/deployment model generally — "This notion of getting in there with your customers and deploying the product... most VCs are generally fairly comfortable with and favorable to." Validated the approach conceptually.
UM wedge choice — Seemed to accept the reasoning. Didn't push back on why UM specifically.
Payer pressure hypothesis — When Thomas articulated it crisply at the end ("payers will realize what United realized"), she said "yeah, yeah, cool" — most engaged she was.
Contract value justification — She assumed "six, seven figure contracts" for this type of work. Validates the revenue potential of the FDE model.

Our Commitments

None.

Their Next Steps

"Keep me posted... happy to take a look as you progress further. Potentially a fit for our stage and sector focus." — Standard lukewarm VC sign-off, not a commitment to next steps.

Investor Insights

Firm profile:

NextGen VP — pre-seed and seed, digital health focus
Deborah spends a lot of time in digital health investing

What they care about:

Differentiation and long-term defensibility (her #1 lens)
Clear vision / end state
Scalable business model (not just consulting)
Hypothesis-driven approach at seed stage

Portfolio comps:

Fourier Health — AI medical record summarization, customized for specific use cases, human in the loop. Mostly health systems. Transition of care, pre-visit summaries. Long sales cycles but sticky contracts.

Market intel shared:

Lumara Health — raising $1.5M pre-seed. Orchestration/knowledge layer for AI agents in healthcare. Benefits navigation + triage automation. Working with CareFirst (TPA), LOI with large East Coast Blues plan (likely CareFirst). Still building product.
Logical Health — payer member engagement. POC with large European insurer. Pre-seed stage.
General view: lots of AI healthcare activity, hard to differentiate, same underlying models. Member engagement side is where she's seen most payer-focused activity.

Pitch feedback (valuable coaching):

Need clearer end-state vision — "strong opinion on the direction the market is headed"
Deep vs. broad needs to be resolved — are you going deeper with 2 clients or broader across many?
Frame it as hypotheses to test at seed stage — not certainties
The "still figuring it out" answer on business model is a risk

Interesting Moments

Thomas raising the moat problem himself — "What's the defensibility if these products are so cross-applicable? It can't be that hard to build." Honest and thoughtful but potentially self-defeating in a pitch context. Better to acknowledge it briefly and pivot to the answer, not dwell on the problem.

Deborah's systems integrator analogy — "In the early days of software, the systems integrator played a very large role. I think there's a version of that in AI." She's seeing this pattern across deals. Worth understanding whether this is a compliment or a concern — VCs may view "next-gen SI" as a services business, not a venture-scale outcome.

"Had to jump to another call" — Cut off at 31 min. She wasn't compelled to extend. Contrast with Primary Ventures (Hannah stayed engaged despite being exhausted) and Refract (offered portfolio intros).

Call dynamic — Thomas carried the narrative, Michael contributed targeted points. Standard dynamic for this team — Thomas leads the story, Michael grounds it with specifics. The awkward texture of this particular call was more about the investor dynamic than the team dynamic.

Raw Transcript

[See above — ~31 minutes, Feb 5 2026]